{"id":396860,"date":"2025-04-03T08:11:16","date_gmt":"2025-04-03T06:11:16","guid":{"rendered":"https:\/\/medizinonline.com\/durvalumab-premiere-immunotherapie-approuvee-pour-les-patients-atteints-de-ls-sclc\/"},"modified":"2025-04-03T08:14:56","modified_gmt":"2025-04-03T06:14:56","slug":"durvalumab-premiere-immunotherapie-approuvee-pour-les-patients-atteints-de-ls-sclc","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/durvalumab-premiere-immunotherapie-approuvee-pour-les-patients-atteints-de-ls-sclc\/","title":{"rendered":"Durvalumab, premi\u00e8re immunoth\u00e9rapie approuv\u00e9e pour les patients atteints de LS-SCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Le durvalumab a \u00e9t\u00e9 approuv\u00e9 en Suisse en monoth\u00e9rapie pour le traitement des patients adultes atteints de cancer du poumon \u00e0 petites cellules inop\u00e9rable (LS-SCLC, <em>limited-stage small cell lung cancer) <\/em>dont la maladie n&#8217;a pas progress\u00e9 apr\u00e8s une chimioradioth\u00e9rapie \u00e0 base de platine (CRT) [1]. Elle offre une nouvelle option th\u00e9rapeutique dont il a \u00e9t\u00e9 d\u00e9montr\u00e9 qu&#8217;elle am\u00e9liore la survie des patients atteints de cette forme agressive de cancer du poumon. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fdurvalumab-premiere-immunotherapie-approuvee-pour-les-patients-atteints-de-ls-sclc%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Le durvalumab a \u00e9t\u00e9 approuv\u00e9 en Suisse en monoth\u00e9rapie pour le traitement des patients adultes atteints de cancer du poumon \u00e0 petites cellules inop\u00e9rable (LS-SCLC, limited-stage small cell lung cancer)&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fdurvalumab-premiere-immunotherapie-approuvee-pour-les-patients-atteints-de-ls-sclc%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":396863,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cancer du poumon \u00e0 petites cellules","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11527,11545,11389,11477],"tags":[13157,23096,37819,23734,13586,81890,20506],"powerkit_post_featured":[],"class_list":["post-396860","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-marche-medecine","category-oncologie","category-pneumologie-fr","tag-cancer-du-poumon","tag-cancer-du-poumon-a-petites-cellules","tag-chimioradiotherapie","tag-durvalumab-fr","tag-immunotherapie-fr","tag-lc-sclc-fr","tag-sclc-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-21 04:25:28","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":396854,"slug":"durvalumab-e-stato-approvato-come-prima-immunoterapia-per-i-pazienti-con-ls-sclc","post_title":"Durvalumab \u00e8 stato approvato come prima immunoterapia per i pazienti con LS-SCLC","href":"https:\/\/medizinonline.com\/it\/durvalumab-e-stato-approvato-come-prima-immunoterapia-per-i-pazienti-con-ls-sclc\/"},"pt_PT":{"locale":"pt_PT","id":396848,"slug":"durvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc","post_title":"Durvalumab aprovado como primeira imunoterapia para doentes com LS-SCLC","href":"https:\/\/medizinonline.com\/pt-pt\/durvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc\/"},"es_ES":{"locale":"es_ES","id":396842,"slug":"durvalumab-aprobado-como-primera-inmunoterapia-para-pacientes-con-ls-sclc","post_title":"Durvalumab aprobado como primera inmunoterapia para pacientes con LS-SCLC","href":"https:\/\/medizinonline.com\/es\/durvalumab-aprobado-como-primera-inmunoterapia-para-pacientes-con-ls-sclc\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/396860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=396860"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/396860\/revisions"}],"predecessor-version":[{"id":398118,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/396860\/revisions\/398118"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/396863"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=396860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=396860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=396860"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=396860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}